Download procabio - Europa Uomo Slovensko

PROCABIO
A European initiative to develop
tailored treatment of prostate cancer
by biomarkers
Objectives PROCABIO
(Tailored treatment of prostate cancer by biomarkers)
 Integration biomarkers in updated and improved model for
indolent prostate cancer
 Integration biomarkers in development of guidelines for
efficient strategies for active surveillance
 Delivery validated biomarker tools that are easily applicable
for high throughput use in clinical and screening settings
 Establishment overall acceptance of active surveillance as
a treatment modality for indolent prostate cancer
For more information, contact [email protected]
PROCABIO consortium (18 partners)
11 clinical & academic partners
5 commercial partners
Erasmus MC (NL)
Abacus Diagnostica (FIN)
Institute of Cancer Research (UK)
Beckman-Coulter (FR)
L’Hôpital Saint-Louis (FR)
Epigenomics (GE)
Lund University (SE)
Gen-Probe Incorporated (USA)
Milan National Cancer Institute (I)
Orion Diagnostica Oy (FIN)
RUNMC (NL)
University of Helsinki (FIN)
2 advisory partners
University of Münster (GE)
EORTC (BE)
University of Sheffield (UK)
Europa Uomo (BE)
University of Tampere (FIN)
University of Turku (FIN)
For more information, contact [email protected]
PROCABIO plan for 3 years
Active surveillance trial in 8 centers according
to PRIAS protocol with 3 years follow-up
Central
biorepository of
blood and urine
Validation in blood, urine or tissue of proteomic
and genomic biomarkers discriminating indolent
and progressive PCa
Biomarker
implementation in
treatment policies
Informing stakeholders on progress and
outcome active surveillance study & biomarker
implementation
Guidelines on
active surveillance
For more information, contact [email protected]
Europe as a scaffold to integrate research for prostate cancer patients
PCa patients involvement (Europa Uomo)
Clinical Centres
implementation
targeted treatment
Marker industries Academic Research
Abacus
Beckman Coulter
Epigenomics
Gen-Probe
Orion
Archival Biomaterials
(via P-Mark, ERSPC, ProtecT)
 Malmö
 Nijmegen
 Munster
 Rotterdam
 Sheffield
 Turku
 Helsinki
Genomic, proteomic,
molecular pathology
Biomarkers
Finland
Belgium
France
Italy
Germany Lithuania
Netherlands
Sweden
UK
Prospective Biomaterials
(via PRIAS-study)
Marker based guidelines for PCa patients (EORTC, EAU)
PROCABIO contact details
PROCABIO coordinator
PROCABIO project manager
Prof. dr. Chris Bangma
Dr. Ellen Schenk-Braat
Erasmus MC
Erasmus MC
Department of Urology
Department of Urology
Room H1096
JNI, room Be362
T. +31-10-7033607
T. +31-10-7043674
F. +31-10-7035838
F. +31-10-7044661
[email protected]
[email protected]
Erasmus MC Department
of Urology
PI Prof. dr. Chris Bangma
50 patients
University Hospital Malmö
Department of Urology
PI Prof. dr. Anders Bjartell
25 patients
Institute of Cancer Research,
London
PI Dr. Chris Parker
100 patients
Tampere University Hospital
Department of Urology
PI Prof. dr. Teuvo Tammela
80-100 patients
Milan National Cancer Institute
PI Prof. dr. Riccardo Valdagni
40 patients
EAU Best paper 2007 by a resident
Integrating Europe for Prostate Cancer
…early detection…
Prostate Cancer
International
study of Active
Surveillance
Biomarker
research
PROCABIO
Prostate Cancer Biomarker
research in clinical setting of
Active Surveillance
Prostate Cancer
Risk Calculator
Patient
organisations
Health care
professionals